How are TERN strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TERN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 10.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$26.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a TERN strangle?

The breakeven for the TERN strangle priced on this page is roughly $52.28 and $57.77 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TERN market-implied 1-standard-deviation expected move is approximately 2.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current TERN implied volatility affect this strangle?

TERN ATM IV is at 10.30% with IV rank near 1.76%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

TERN Strangle Strategy

TERN (Terns Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

TERN (Terns Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.77B, a beta of -0.38 versus the broader market, a 52-week range of 2.655-53.19, average daily share volume of 5.8M, a public-listing history dating back to 2021, approximately 59 full-time employees. These structural characteristics shape how TERN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.38 indicates TERN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on TERN?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current TERN snapshot

As of May 15, 2026, spot at $54.63, ATM IV 10.30%, IV rank 1.76%, expected move 2.95%. The strangle on TERN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on TERN specifically: TERN IV at 10.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a TERN strangle, with a market-implied 1-standard-deviation move of approximately 2.95% (roughly $1.61 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TERN expiries trade a higher absolute premium for lower per-day decay. Position sizing on TERN should anchor to the underlying notional of $54.63 per share and to the trader's directional view on TERN stock.

TERN strangle setup

The TERN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TERN near $54.63, the first option leg uses a $57.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TERN chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TERN shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$57.50	$0.13
Buy 1	Put	$52.50	$0.14

TERN strangle risk and reward

Net Premium / Debit: -$26.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$26.50
Breakeven(s): $52.28, $57.77
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

TERN strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on TERN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$5,222.50
$12.09	-77.9%	+$4,014.71
$24.17	-55.8%	+$2,806.92
$36.24	-33.7%	+$1,599.13
$48.32	-11.5%	+$391.34
$60.40	+10.6%	+$263.44
$72.48	+32.7%	+$1,471.23
$84.56	+54.8%	+$2,679.02
$96.63	+76.9%	+$3,886.81
$108.71	+99.0%	+$5,094.60

When traders use strangle on TERN

Strangles on TERN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TERN chain.

TERN thesis for this strangle

The market-implied 1-standard-deviation range for TERN extends from approximately $53.02 on the downside to $56.24 on the upside. A TERN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current TERN IV rank near 1.76% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TERN at 10.30%. As a Healthcare name, TERN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TERN-specific events.

TERN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TERN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TERN alongside the broader basket even when TERN-specific fundamentals are unchanged. Always rebuild the position from current TERN chain quotes before placing a trade.

Frequently asked questions

What is a strangle on TERN?: A strangle on TERN is the strangle strategy applied to TERN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With TERN stock trading near $54.63, the strikes shown on this page are snapped to the nearest listed TERN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are TERN strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TERN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 10.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$26.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a TERN strangle?: The breakeven for the TERN strangle priced on this page is roughly $52.28 and $57.77 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TERN market-implied 1-standard-deviation expected move is approximately 2.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on TERN?: Strangles on TERN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TERN chain.
How does current TERN implied volatility affect this strangle?: TERN ATM IV is at 10.30% with IV rank near 1.76%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.